CHALFONT ST. GILES, UK and PASCHING, AUSTRIA – 12 April 2016 – GE Healthcare’s Life Sciences business today announced that its European manufacturing and distribution site for sterile liquids has expanded its capabilities to include production of large volumes of buffers, process liquids and cell culture media, and launched a rapid production service for prototype... Read more
WUHAN, China and AMERSHAM, England, Feb. 25, 2016 /PRNewswire/ — JHL Biotech (TPEx: 6540) and GE Healthcare’s Life Sciences business (NYSE: GE) are proud to announce mechanical completion of JHL Biotech’s JHL-1 biopharmaceutical manufacturing facility in the Biolake area of Wuhan, China. The campus was built to be compliant with the highest international standards, and after site validation is completed in June... Read more
BARRINGTON, Ill., November 9, 2015 — GE Healthcare (NYSE: GE) announced today it is expanding its U.S. healthcare consulting business with the acquisition of The Camden Group, one of the nation’s leading population health & strategic advisory firms. GE Healthcare Camden Group will act as the U.S. business unit of GE Healthcare’s global advisory firm,... Read more
Tokyo, Japan and Chalfont St Giles, UK – 7 September 2015 – GE Healthcare today announced that Fujifilm Kyowa Kirin Biologics has selected GE Healthcare’s innovative MabSelect SuRe™ LX high-affinity chromatography media for the manufacture of monoclonal antibodies. http://www.genewsroom.com/press-releases/fujifilm-kyowa-kirin-biologics-selects-ge%E2%80%99s-innovative-mabselect-sure-lx-media Read more
Aubagne, France; Goettingen, Germany and Chalfont St. http://www.genewsroom.com/press-releases/sartorius-stedim-biotech-and-ge-healthcare-sign-worldwide-oem-supply-agreement-281604 Read more
PHILADELPHIA, PA – August 25, 2015 – Academic medical centers across the U.S. are experiencing increasing pressure to enhance value – deliver higher quality at lower cost – as they continue to face challenges related to outcomes, cost control, market competition, and other dynamics. Initiatives to promote value typically involve reimbursement arrangements between health insurers... Read more
Beckman Coulter Diagnostics and COPAN, a company committed to innovation in the field of pre-analytics, recently announced that Beckman Coulter Diagnostics and COPAN Group have entered into an amendment to their distribution agreement that expands their relationship into new products and geographic territories. Additional products include COPAN’s WASPLab automated, front-end robotic specimen processing, full lab... Read more
MENLO PARK, Calif., May 5, 2015 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (Nasdaq:PACB), provider of the PacBio® RS II Sequencing System, today announced that it has achieved a second development milestone under its development, commercialization and license agreement with F. Hoffman-La Roche Ltd (Roche), earning an additional $10 million.The development, commercialization and license... Read more
MENLO PARK, Calif. and BILLERICA, Mass., May 5, 2015 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (Nasdaq:PACB), provider of the PacBio® RS II Sequencing System, and RainDance Technologies, Inc., a genomics tools company dedicated to simplifying the analysis of complex genetic diseases, today announced their entry into a co-development and co-marketing agreement to commercialize... Read more
MENLO PARK, Calif., March 23, 2015 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc., (Nasdaq:PACB) provider of the PacBio® RS II Sequencing System, today announced that the company has launched a Certified Service Provider (CSP) program and added new informatics partners to meet the increasing demand for Single Molecule, Real-Time (SMRT®) Sequencing and data analysis... Read more